Literature DB >> 32294246

Efficient screening of predictive biomarkers for individual treatment selection.

Shonosuke Sugasawa1, Hisashi Noma2.   

Abstract

The development of molecular diagnostic tools to achieve individualized medicine requires identifying predictive biomarkers associated with subgroups of individuals who might receive beneficial or harmful effects from different available treatments. However, due to the large number of candidate biomarkers in the large-scale genetic and molecular studies, and complex relationships among clinical outcome, biomarkers, and treatments, the ordinary statistical tests for the interactions between treatments and covariates have difficulties from their limited statistical powers. In this paper, we propose an efficient method for detecting predictive biomarkers. We employ weighted loss functions of Chen et al. to directly estimate individual treatment scores and propose synthetic posterior inference for effect sizes of biomarkers. We develop an empirical Bayes approach, namely, we estimate unknown hyperparameters in the prior distribution based on data. We then provide efficient screening methods for the candidate biomarkers via optimal discovery procedure with adequate control of false discovery rate. The proposed method is demonstrated in simulation studies and an application to a breast cancer clinical study in which the proposed method was shown to detect the much larger numbers of significant biomarkers than existing standard methods.
© 2020 The International Biometric Society.

Entities:  

Keywords:  empirical Bayes; false discovery rate; optimal discovering procedure; propensity score

Year:  2020        PMID: 32294246     DOI: 10.1111/biom.13279

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  1 in total

1.  A permutation procedure to detect heterogeneous treatment effects in randomized clinical trials while controlling the type I error rate.

Authors:  Jack M Wolf; Joseph S Koopmeiners; David M Vock
Journal:  Clin Trials       Date:  2022-05-09       Impact factor: 2.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.